1. Introduction
The Disrupted in Schizophrenia 1 (DISC1) gene was found mutated when studying a chromosomal translocation t(1;11)(q42.1;q14.3) in a Scottish family; this translocation correlated with cases of schizophrenia, bipolar disorder and major depression [1,2]. Further studies also found that the truncation of this gene in an American family segregated with cases of schizophrenia [3].
Since the discovery of this translocation, many groups have invested their efforts in understanding the role of DISC1 protein, with the hope of revealing new mechanisms that could explain the neurobiology behind mental disease. Therefore, DISC1 was proposed to be involved in diverse processes such as neurogenesis [4,5], synapse regulation [6,7,8,9,10], neurite outgrowth [6,11,12], and neural migration and proliferation [13,14,15]. Also, yeast two hybrid experiments [16] and other molecular studies have revealed several important interacting partners of DISC1 including GSK3β [5], PDE4B [17], Rac1 [8], Girdin [18] or TNIK [9] among others. Thus, DISC1 might act as a molecular scaffold, providing cohesion and coordination among different biological events in the brain [19].
To acquire a deeper understanding of the mechanisms of action of DISC1, several proteomic analyses have been conducted to specifically address the role of the truncated isoform of DISC1 on the cellular proteome of neural cells [20,21]. In this study, we decided to specifically address the role of DISC1 loss of function, for that we carried out an unbiased proteomic analysis in DISC1-silenced neurons.
We report that DISC1 alters the expression of many relevant proteins related to neurodevelopment and synaptic function, reinforcing the idea that DISC1 is a key molecular link bridging neurodevelopmental functions with the regulation of synaptic formation and neurosignaling processes.
2. Results 2.1. Proteomic Analysis
Cell extracts from control and DISC1 knockdown murine primary neurons (Figure S1) were subjected to proteomic analysis. Four bidimensional gels for the silenced condition versus four of the control condition were analyzed. 3474 identical spots per gel were detected (Figure S2) and 75 of them were found differentially expressed with a fold change ≥2 and p value < 0.05 (Table S1). 68 of these spots were identified using mass spectrometry, corresponding to 48 unique proteins (Table 1). The functions of these proteins were mainly related to neurodevelopmental processes or synaptic function (Table 1, Figure S3). Particularly, 19 of them were related to neurodevelopmental processes (Table 1) and other 19 unique proteins were related to synaptic function (Table 1). Of note, 7 of these proteins have shared functions (Table 1, Figure S3). Therefore, these results suggest that DISC1 plays an important role linking these two processes.
Remarkably, some of the identified proteins have previously been described as DISC1 binding partners, it is the case of 14-3-3 proteins [12] and LIS1 [22], while CRMP-2 has been identified as a possible DISC1 interactor [16]. However, to the best of our knowledge, this is the first time that DISC1 has been found to also alter their expression. As well, we could identify some of the proteins as substrates of similar enzymes; this is the case of stathmin, CRMP-2, and MAP1B. These proteins are known to be phosphorylated by GSK3β to exert their functions.
2.2. Ingenuity Pathway
To identify common molecular pathways regulated by DISC1 in our sample set we used the Ingenuity Pathways Analysis (IPA) software. The 5 top canonical pathways involved in our analysis are represented in Table 2. It is interesting that CRMP (collapsin response mediator protein) family was highlighted in the analysis as part of the Semaphorin signaling in neurons, since this signaling cascade is known to play an important role in neuronal differentiation and axonal growth [23,24]. Previous studies also concluded that the overexpression of the truncated isoform of DISC1 leads to dysregulation of Semaphorin signaling [20]. This could be a corroborative evidence for the fact that DISC1 expression has to be tightly and precisely regulated in a small window and that both, above and below that window you have dysregulation of similar signaling pathways.
The top molecular and cellular functions identified by IPA are represented in Table 3. The analysis particularly highlighted proteins involved in neurite outgrowth and branching of neurons.
2.3. DISC1 Alters the Expression of Neurodevelopmental Related Proteins
Considering the results obtained by IPA analysis we focused on the collapsin response mediator proteins (CRMPs) to perform our validations. These proteins constitute a family of five homologous cytosolic proteins (CRMP-1-5) involved in microtubule regulation. All of them are phosphorylated and highly expressed in the developing and adult nervous system where they play important roles in neuronal development and maturation [25]. Six spots corresponding to CRMP-5, CRMP-3, CRMP-2 and CRMP-1 were differentially expressed in silenced vs. control cells (Table 1) in our study; in all cases the proteins were upregulated in DISC1 silenced cells.
Particularly, CRMP-2 has been described as a candidate gene for susceptibility to schizophrenia [26] and was found upregulated in a proteomic study performed with brain samples from patients with bipolar disorder, schizophrenia and major depression [27]. We showed differential expression of multiple CRMP2 isoforms upon DISC1 silencing (Figure 1) in primary neurons. The existence of different isoforms of CRMP2 has been highlighted in several studies [28,29]. Here, CRMP2 was detected as three isoforms (labelled 1 to 3). Isoforms 1 and 2, most likely corresponding to CRMP2A and CRMP2B [28] were found to be downregulated in DISC1-silenced cells, while isoform 3 was upregulated. A similar pattern was observed using antibodies that recognize CRMP-2 phosphorylated at Thr-514 (Figure 1). Therefore, isoform 3 most likely corresponds to the spot that was differentially expressed in our proteomic analysis.
Some studies described this isoform as a calpain-associated degradation product [30,31], while others highlight its role in neurite outgrowth inhibition [32]. If this is the case, it suggests that DISC1 silencing leads to increased expression of CRMP-2 and, as a result, inhibition of neurite outgrowth. Of note, Septin-5, a protein that directly interacts with CRMP-2, was also found differentially expressed in our study (Table 1).
2.4. DISC1 Alters the Expression of Synaptic Function Related Proteins
We also consider of great relevance that endocytosis was highlighted under the top molecular and cellular functions in our IPA analysis (Table 3). Endocytosis and exocytosis are crucial processes for neurotransmission [33] and regulated by SNARE and SM proteins (Sec1/Munc18-like proteins) [34]. In particular, syntaxin-7 (member of the SNARE complex present on plasma membrane) and syntaxin binding protein (STXBP, also known as MUNC18) were found upregulated in DISC1-silenced cells (Table 1). Other proteins that regulate the exocytic processes responsible for neuronal communication are Rab proteins [35], which catalyze SNARE complex assembly [36]. In this study four different Rab proteins were found differentially expressed in DISC1-silenced cells (Table 1).
2.5. DISC1 Silenced SH-SY5Y Cells Show Impaired Neurite Outgrowth
To further test that silencing of DISC1 results in disruption of neural development, we performed a morphological study in SH-SY5Y cells in which DISC1 was silenced [37]. The absence of DISC1 in this cell line resulted in morphological changes (Figure 2). Thus, upon retinoic acid-induced differentiation, DISC1-silenced cells exhibited fewer and shorter neurites (Figure 2, Figure S4).
3. Discussion
We have taken advantage of a well-established murine primary neuron DISC1 knock-down experimental system [8,14,37] to carry out an unbiased proteomic analysis and thus, identify proteins which have their expression affected by DISC1.
The results of our analysis highlight the importance of DISC1 both in neurodevelopment and synaptic regulation. Both functions have been already ascribed to DISC1; however, this study describes new important routes to explore, as the effect DISC1 silencing on the expression of CRMP family of proteins. This could be a powerful mechanism to further investigate considering the relevance this family of proteins has in the neurobiology of mental disease [27,38,39,40].
Furthermore, DISC1 knockdown resulted in a neurite outgrowth deficit in RA-treated SH-SY5Y cells. Previous studies have reported an impaired neurite outgrowth in cell models that overexpress mutant isoforms of DISC1 [11,41] and an increase of neurite outgrowth was seen in PC12 cells that overexpress DISC1 [42]. Therefore, our study reinforces the idea that the loss of function of DISC1 is critical for proper regulation of neurite outgrowth. In this direction, other studies have previously shown DISC1 silencing affected neurite outgrowth using PC12 cells [14]. We have to consider neurite outgrowth in PC12 cells is a result of two processes, neural differentiation and subsequent neurite extension, so the effects of silencing may be interpreted as measuring an effect on either/both processes. In contrast, SH-SY5Y cells are already neuronal and forming neurites, so we could compare neurite length and the effect is specific to neurite outgrowth.
At the same time, we have found that several proteins that participate in synaptic membrane trafficking and synapse formation are altered in DISC1 silenced neurons, such as syntaxin 7, MUNC-18, cadherin-13, and Rab proteins (Table 1), but we cannot conclude whether trafficking is up- or downregulated in our system. Previous studies have shown that DISC1 enhances the transport of synaptic vesicles, therefore we could expect that knocking down DISC1 expression produced an attenuated vesicle transport in primary cortical neurons [43].
Summarizing, our study shows that DISC1 works as an important modulator of proteins that are directly involved both in neurodevelopment and in adult synaptic regulation, representing a unifier factor of two seemingly different categories.
4. Materials and Methods 4.1. Antibodies
Commercial antibodies specific for the following proteins were used: CRMP-2, p(Thr514)CRMP-2, Stathmin, p(Ser38)Stathmin (1:1000; Cell Signaling Technology, Danvers, MA, USA); tubulin, GAPDH (1:5000; Sigma-Aldrich, St. Louis, MO, USA); the human DISC1-specific antibody 14F2 has been previously described [44]; the mouse DISC1-specific antibody D27 was a kind gift from Merck (Kenilworth, NJ, USA). Goat anti-rabbit (1:2000; Dako Cytomation, Glosstrup, Denmark), sheep anti-mouse (1:5000; GE Healthcare Amersham Bioscience, Uppsala, Sweden) and donkey anti-goat (1:2000; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) were used as secondary antibodies.
4.2. Cell Culture
SH-SY5Y neuroblastoma cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in 1:1 Earle’s Balanced Salt Solution (EBSS)- F12HAM (Sigma Aldrich) with 15% fetal bovine serum (FBS) (Gibco, Life Technologies, Gaithesburg, MD, USA), 1% Glutamine (Gln) (Sigma Aldrich), 1% non-essential amino acids (NEAA) (Sigma Aldrich), and 1% Penicillin-Streptomycin (P/S) (Invitrogen). 293FT cells (Invitrogen) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich) with 10% FBS, 1% sodium pyruvate (Sigma Aldrich), 1% NEAA, 1% Gln, and 1% P/S.
Murine cortex and hippocampal primary neurons were prepared from 14–15 days embryos (see below ethical statement). Pregnant dams were killed by cervical dislocation in accordance with institutional guidelines for care and use of animals. The embryos were maintained and dissected in PBS Ca/Mg (Invitrogen) supplemented with 33 mM glucose. Pooled tissue was mechanically dissociated, treated with trypsin (Invitrogen) and DNaseI (Roche Applied Science, Mannheim, Germany) and resuspended in Neurobasal medium (Invitrogen) supplemented with 50X B27 (Invitrogen), 0.55g/100mL glucose (Sigma Aldrich), 42 mg/100 mL sodium bicarbonate (Sigma Aldrich), 1% P/S and 1% glutamine. The cells were plated on poly-D-lysine (Sigma Aldrich) coated Petri dishes. Cultures were maintained in serum free medium at 37 °C in 95% air/5% CO2.
4.3. Ethics Statement
Animal experiments were carried out in accordance with the European Union Council Directive 86/609/EEC, and were approved by the University of Santiago de Compostela Ethics Committee (protocol 15005AE/12/FUN 01/PAT 05/JRR2, 5 January 2012).
4.4. DISC1 Silencing
For DISC1 knock-down in murine primary neurons, we chose a validated shRNA construct developed by Akira Sawa’s group (DISC1 RNAi #1) that has been shown to specifically decrease the amount of DISC1 in cortical neural cell cultures [8,14,37]. The commercial pLK0.1-puro non-mammalian shRNA control construct from Sigma Aldrich (reference: SHC002) was used as a scramble control. Lentiviruses were produced by calcium phosphate triple co-transfection of shRNA (see Table S3 and Figure S1 in Supporting Information), VSVG and ΔR8.9 constructs into 293FT packaging cells. Virus-containing medium was collected 48 h after transfection, and added (10 mL of lentiviral solution/3 × 106 neurons) to the medium of primary neurons at 7 DIV. The medium was changed 24 h after infection, and incubation continued for 72 h.
In SH-SY5Y cells, DISC1 was silenced using commercial Mission® shRNA lentiviral transduction particles (Sigma Aldrich, reference NM_018662) containing two alternative PLKO.1-Puro-CMV shRNA plasmids (Table S2 in Supporting Information). Mission® pLKO.1-puro non-mammalian shRNA particles (reference: SHC002V) were used as control. Stable cell lines were generated for any of these constructs after selection with puromycin as previously described [37].
4.5. Sample Preparation for Proteomic Studies
Cells (confluent 100 mm plates) were washed twice with cold PBS and solubilized in lysis buffer (20 mM HEPES, 2 mM EGTA, 1 mM DTT, 1 mM sodium orthovanadate, 1% Triton X-100, 10% Glycerol, 2 µM leupeptin, 400 µM PMSF, 50 µM β-glycerophosphate, 100 µg/mL Trasylol). The cells were scraped on ice for 10 min, incubated on ice for 30 min with periodic vortexing every 5 min and centrifuged for 20 min at 14,000 g, 4 °C. The supernatant was saved and the pellet discarded. The protein content was determined using the BCA protein assay kit (Pierce Chemical). Proteins were precipitated with 60% trichloroacetic acid (TCA) in acetone. After 2–3 acetone washes, proteins were dissolved in 500 μL of 2D sample buffer (5 M urea, 2 M thiourea, 2 mM tributyl-phosphine, 65 mM DTT, 65 mM CHAPS, 0.15 M NDSB-256, 1 mM sodium vanadate, 0.1 mM sodium fluoride, and 1 mM benzamidine). Ampholytes (Servalyte 4–7) were added to the sample to a final concentration of 1.6% (v/v).
4.6. Proteomic Studies
The primary neuron cell lysates were subjected to two-dimensional gel electrophoresis (2-DE). Protein quantitation was performed with the Coomassie plus protein reagent (Thermo Scientific, Asheville, NC). Five hundred micrograms of protein were loaded onto each gel to allow detection of low abundance proteins. Four gels per study group (DISC1 knock-down and control) were compared. Immobilized pH gradient (IPG) strips (4–7, 24 cm, GE Healthcare, Uppsala, Sweden) were rehydrated in the sample, and isoelectric focusing (IEF) was performed in a Multiphor (GE Healthcare) for 85 kVh at 17 °C. Following focusing, the IPG strips were immediately equilibrated for 15 min in 4 M urea, 2 M thiourea, 130 mM DTT, 50 mM Tris pH 6.8, 2% w/v SDS, 30% v/v glycerol. Later, the strips were placed for 15 min in the same buffer, in which DTT was replaced by 4.5% iodoacetamide (Sigma Aldrich). The IPG strips were placed on top of the second dimension gels and embedded with 0.5% melted agarose. Proteins were separated in the second dimension by SDS-polyacrylamide gel electrophoresis (PAGE) on 10% gels at run conditions of 10 °C, 20 mA per gel for 1 h, followed by 40 mA per gel for 4 h by using an Ettan Dalt 6 system (GE Healthcare). Following electrophoresis, gels were fixed in 10% methanol/7% acetic acid for 1 h, and stained overnight with Sypro Ruby fluorescent dye (Lonza, Switzerland). After staining, gels were washed for 1 h in 10% methanol/7% acetic acid, and scanned in a Typhoon 9410 (GE Healthcare).
4.7. Differential Image Analysis
Image analysis was performed with the Ludesi REDFIN 3 Solo software (Ludesi, Malmö, Sweden). The integrated intensity of each of the spots was measured, and the background corrected and normalized. Differential expression of proteins was defined on the basis of ≥2-fold change between group averages and p < 0.05.
4.8. Mass Spectrometric Analysis
Spots of interest were carefully excised and subjected to in-gel digestion with trypsin [45]. Tryptic digests were analyzed using a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems). Dried peptides were dissolved in 4 µL of 0.5% formic acid. Equal volumes (0.5 µL) of peptide and matrix solution, consisting of 3 mg alpha-cyano-4-hydroxycinnamic acid (α-CHCA) dissolved in 1 mL of 50% acetonitrile in 0.1% trifluoroacetic acid, were deposited using the thin layer method, onto a 384 Opti-TOF MALDI plate (Applied Biosystems). MS spectra were acquired in reflectron positive-ion mode with a Nd:YAG, 355 nm wavelength laser, averaging 1000 laser shots and using at least three trypsin autolysis peaks as internal calibration. All MS/MS spectra were performed by selecting the precursors with a relative resolution of 300 (FWHM) and metastable suppression. Automated analysis of mass data was achieved by using the 4000 Series Explorer Software V3.5. MS and MS/MS spectra data were combined through the GPS Explorer Software v3.6. Database search was performed with the Mascot v2.1 search tool (Matrix Science, London, UK) screening SwissProt (release 56.0). Searches were restricted to mouse taxonomy allowing carbamidomethyl cysteine as a fixed modification and oxidized methionine as potential variable modification. Both the precursor mass tolerance and the MS/MS tolerance were set at 30 ppm and 0.35 Da, respectively, allowing 1 missed tryptic cleavage site. All spectra and database results were manually inspected in detail using the above software. Protein scores greater than 56 were accepted as statistically significant (p < 0.05), considering positive the identification when protein score CI (confidence interval) was above 98%. In case of MS/MS spectra, total ion score CI was above 95%.
4.9. SDS-PAGE and Western Blotting
A total of 50 µg of protein was mixed with Laemmli sample buffer (BioRad), heated at 100 °C for 10 min, spun, and the supernatant loaded on a 7.5% SDS-PAGE gel. Samples were subjected to electrophoresis and transferred to polyvinylidenedifluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The conditions of the electrophoresis were 200 V, 1 h. Electrophoresis was performed using a Mini-PROTEAN 3 cell electrophoresis system (BioRad). The transfer was performed in a Trans-blot SD semi-dry transfer cell (BioRad) using the following conditions: 0.8 mA/cm2, 90 min. The PVDF membranes were blocked in 5% non-fat milk in PBS-0.1% Tween solution overnight at 4 °C, then 4 washes of 5 min with PBS-0.1% Tween20 were performed, and the membrane was incubated with the primary antiserum (in 5% BSA in PBS-0.1%Tween20) for 1 h at room temperature, washed again and incubated with the peroxidase-conjugated secondary antibody (in PBS-0.1% Tween20), and subjected to 4 washes of 5 min each with PBS-0.1% Tween20. Finally the membrane was incubated with the chemiluminescence solution Luminata Forte Western HRP substrate (Merck Millipore). To develop the membranes Hypercassette (GE Healthcare) and Amersham Hyperfilm ECL (GE Healthcare) were used.
4.10. Ingenuity Pathway
Ingenuity Pathway Analysis software (Ingenuity Systems, CA, USA) was used to investigate interactions between all the 48 identified proteins. Interactive pathways were generated to observe potential direct and indirect relations among the differentially expressed proteins. To test the enriched pathways we consider as settings direct and indirect relationships that were experimentally observed.
4.11. Neurite Outgrowth Assays
Stable SH-SY5Y cell lines generated using TRCN0000118997 (Silenced 1), TRCN0000119000 (Silenced 4) and non-target shRNAs were cultured for 7 and 14 days in medium containing 10 µM retinoic acid (RA) (Sigma Aldrich). To analyze neurite outgrowth, images of live cells were taken under a microscope and processed using Image J software (http://rsb.info.nih.gov/ij). Cells with and without neurites longer than two cell bodies were counted in photomicrographs of the differentiated control and DISC1-silenced cells.
4.12. Immunocytochemistry of SH-SY5Y Cells
Retinoic acid-treated cells were fixed in paraformaldehyde and immunostained for β3-tubulin and nuclei were visualized using DAPI, as previously described by the authors of [46].
4.13. Statistical Analysis
One-way ANOVA was employed in the proteomic analysis to determine statistically significant differences between groups of samples. For each spot ID, ANOVA p-value was calculated using the quantified and normalized spots volumes for the matched spot in each of the images. Differential expression of proteins was defined on the basis of ≥2-fold change between group averages and p < 0.05.
In the neurite outgrowth assay, three fields of up to 100 cells were analyzed for each condition and the experiment was performed twice. Statistical analysis was performed using a non-parametric unpaired Mann-Whitney U-test (two-tailed); results were considered significant with p < 0.05.
5. Conclusions
This study shows DISC1 disrupts the expression of a number of proteins involved in neurodevelopment and synaptic function. Thus, DISC1 acts as a key modulator of two mechanisms that have been critically implicated in the development of mental disease.
Figure 1. DISC1 differentially affects CRMP2 isoform levels. (a) Western blot of CRMP2 and pCRMP2 proteins. The total content of CRMP2 falls in DISC1 silenced cells, and the smallest one, thought to be a cleavage product, rises. The three isoforms are indicated (1-3). (b) Densitometric analysis of CRMP2 bands 2 and 3 (n = 4, * p <0.05).
Figure 2. DISC1-silenced cells show morphological impairment in neurite outgrowth assays. Cells were treated with retinoic acid (RA) for 7 and 14 days and neurite length was measured using Image J. (A) Fluorescence images of SH-SY5Y cells expressing control and DISC1 shRNAs treated with RA for 7 days and immunostained for βIII-tubulin (red); nuclei were stained using DAPI (blue). (B,C) Average neurite length ± SD; (**** p <0.0001, significantly different between control and DISC1-silenced cells, n > 200 for each cell line). (D,E) Frequency (percentile) of cells according to neurite length at 7 days (D) and 14 days (E) for each cell population; p <0.0001 control vs. silenced 1 at 7 and 14 days, p <0.0001 control vs. silenced 4 at 7 days, p <0.001 control vs. silenced 4 at 14 days (Mann-Whitney U test).
Function | Protein | Fold Change | p Value |
---|---|---|---|
Neurite outgrowth or neural migration | Dihydropyrimidinase-related protein 5 (CRMP-5) | 2.59 | 3.066 × 10−5 |
Dihydropyrimidinase-related protein 3 (CRMP-3) | 3.12, 2.23 | 1.469 × 10−4, 2.894 × 10−4 | |
Dihydropyrimidinase-relatedprotein 2 (CRMP-2) | 2.21, 2.03 | 2.457 × 10−4, 0.059 | |
Dihydropyrimidinase-related protein 1 (CRMP-1) | 2.10 | 9.180 × 10−5 | |
Tubulin alpha-1A chain (TBA1A) | 2.01,2.99,2.13 | 0.0043, 1.326 × 10−4, 4.067 × 10−4 | |
Tubulin beta-2B chain (TBB2B) | Inf, 2.42 | 0.0065, 0.0156 | |
Microtubule-associated protein (MAP1B) | 2.04, 2.20,3.03 | 3.661 × 10−7, 2.894 × 10−4, 2.717 × 10−5 | |
14-3-3 protein epsilon (14-3-3ε) | 2.67, 3.19 | 6.713 × 10−5, 1.854 × 10−4 | |
14-3-3 protein zeta/delta (14-3-3θ/Δ) | 8.42, 2.63, 3.26, 3.88, 3.89, 6.81, 3.82, 6.20 | 3.028 × 10−6, 2.334 × 10−4, 1.579 × 10−4 9.307 × 10−4, 0.021, 2.080 × 10−5, 0.0022, 2.572 × 10−6 | |
14-3-3 protein gamma (14-3-3γ) | 3.24, 2.30 | 6.104 × 10−5, 0.0084 | |
Platelet-activating factor acetylhydrolase IB (Lis-1) | 2.48 | 0.0049 | |
Stathmin (STMN) | 2.12, 4.64 | 8.206 × 10−4, 1.021 × 10−4 | |
Syntaxin-7 (STX7) | 2.13 | 0.0022 | |
Tropomyosin alpha-3 chain (TPM3) | 2.88 | 0.0115 | |
Actin, cytoplasmic 2 (ACTG) | 4.94, 2.95 | 4.398 × 10−5, 1.081 × 10−5 | |
Cadherin-13 (CAD13) | 2.31 | 0.0108 | |
Calreticulin (CALR) | 2.60 | 0.0088 | |
Septin-5 (SEPT5) | 2.15 | 0.0034 | |
Apolipoprotein A-I (APOA1) | 2.41 | 9.215 × 10−5 | |
Dynamin 1 (DYN1) | 4.33 | 1.440 × 10−4 | |
Dynamin 1 (DYN1) | Dihydropyrimidinase-related protein 5 (CRMP-5) | 2.59 | 3.066 × 10−5 |
Dihydropyrimidinase-relatedprotein 2 (CRMP-2) | 2.21, 2.03 | 2.457 × 10−4, 0.059 | |
Microtubule-associated protein (MAP1B) | 2.04, 2.20, 3.03 | 3.661 × 10−7, 2.894 × 10−4, 2.717 × 10−5 | |
Transitional endoplasmic Reticulum ATPase (TERA) | 2.21 | 5.537 × 10−4 | |
Stathmin (STMN) | 2.12, 4.64 | 8.206 × 10−4, 1.021 × 10−4 | |
Syntaxin-binding protein 1 (STXB1) | 3.43 | 0.0010 | |
Syntaxin-7 (STX7) | 2.13 | 0.0022 | |
Ras-related protein Rab-1A (RAB1A) | 2.01 | 0.0023 | |
Ras-related protein Rab-2A (RAB2A) | 2.43 | 4.164 × 10−4 | |
Ras-related protein Rab-11B (RB11B) | 3.25 | 0.0305 | |
Ras-related protein Rab-18 (RAB18) | 3.23 | 5.527 × 10−4 | |
Cadherin-13 (CAD13) | 2.31 | 0.0108 | |
Rho GDP-dissociation inhibitor 2 (GDIR2) | 2.28 | 1.061 × 10−4 | |
Phosphatidylethanolamine-binding protein 1 (HCNP) | 3.84, 6.49 | 4.081 × 10−4, 2.377 × 10−4 | |
Calreticulin (CALR) | 2.60 | 0.0088 | |
Adaptin ear-binding coat-associated protein 1 (NECP1) | 2.51 | 6.028 × 10−5 | |
Neuronal calcium sensor 1 (NCS1) | 2.24 | 9.215 × 10−5 | |
Dynamin 1 (DYN1) | 4.33 | 1.440 × 10−4 |
1 All the proteins had a fold change > 2 and p value < 0.05. Fold change in red indicates that the protein is overexpressed in DISC1 silenced cells, while fold change in black indicates a downregulation in DISC1 silenced cells.
Name | p Value | Proteins |
---|---|---|
14-3-3 mediated signaling | 4.99 × 10−7 | TUBA1A, 14-3-3G, TUBB2B, PDIA3,1 4-3-3E, 14-3-3Z |
Semaphorin signaling in neurons | 5.28 × 10−6 | CRMP3, CRMP1, CRMP2, CRMP5 |
Remodeling of epithelial adherent junctions | 1.52 × 10−5 | DNM1L, TUBA1A, ACTG1, TUBB2B |
Cell cycle: G2/M DNA damage checkpoint regulation | 1.75 × 10−4 | 14-3-3G, 14-3-3E, 14-3-3Z |
PI3K/AKT signaling | 1.87 × 10−4 | 14-3-3G, 14-3-3E, HSP90AA1, 14-3-3Z |
Name | p Value | Proteins |
---|---|---|
Outgrowth of cells | 3.94 × 10−8 | DNM1L, TUBA1A, HBA1/HBA2, CRMP3, MAP1B, SET, PDIA3, CRMP2, 14-3-3G, HSP90AA1, CRMP5 |
Patterning of dendrites | 9.56 × 10−8 | CRMP1, CRMP2, GDA |
Outgrowth of neurites | 1.94 × 10−7 | DNM1L, TUBA1A, HBA1/HBA2, DPYSL3, MAP1B, SET, PDIA3, CRMP2, 14-3-3Z, CRMP5 |
Branching of neurons | 2.53 × 10−7 | DNM1L, HNRNPK, CRMP3, MAP1B, PDIA3, CRMP1, CRMP2, CRMP5, GDA |
Organization of cytoplasm | 7.08 × 10−7 | CDH13, RAB2A, HNRNPK, CRMP1, CRMP2, CRMP5, STMN1, CALR, TPM3, DNM1L, ACTG1, PEX5, CRMP3, MAP1B, RAB1A, PDIA3, HSP90AA1, GDA |
Fibrogenesis | 8.53 × 10−7 | CALR, CDH13, TPM3, ACTG1, CRMP3, MAP1B, APOA1, CRMP2, GDA, STMN1 |
Endocytosis | 1.39 × 10−6 | CALR, CDH13, HNRNPK, MAP1B, RAB1A, APOA1, CRMP2, VCP, HSP90AA1, NECAP1 |
Neuritogenesis | 2.09 × 10−6 | DNM1L, HNRNPK, CRMP3, MAP1B, PDIA3, CRMP1, CRMP2, HSP90AA1, CRMP5, GDA, STMN1 |
Branching of neurites | 2.50 × 10−6 | DNM1L, HNRNPK, MAP1B, PDIA3, CRMP1, CRMP2, CRMP5, GDA |
Microtubule dynamics | 3.39 × 10−6 | CDH13, RAB2A, HNRNPK, CRMP1, CRMP2, CRMP5, STMN1, TPM3, DNM1L, ACTG1, CRMP3, MAP1B, PDIA3, HSP90AA1, GDA |
Supplementary Materials
Supplementary materials can be found at https://www.mdpi.com/1422-0067/20/1/119/s1.
Author Contributions
Conceptualization, A.R., C.R.-S., R.M.K., A.G., and J.R.R.; methodology, A.R., C.R.-S., R.M.K., A.G., and J.R.R.; software, A.R. and A.G.; validation, A.R., C.R.S.; formal analysis, A.R., C.R.-S., I.G.-E. and J.A.; investigation, A.R., C.R.-S., I.R., I.G.-E., J.A., S.V.; resources, C.K., J.A., R.M.K., A.G. and J.R.R.; data curation, A.R., C.R.-S., J.A., R.M.K. and J.R.R.; writing-original draft preparation, A.R., C.R.-S. and J.R.R.; writing-review and editing, C.K., R.M.K. and A.G.; visualization, A.R. and I.G.-E.; supervision, A.G., R.M.K. and J.R.R.; project administration, J.R.R.; funding acquisition, C.K., R.M.K., A.G., I.G.-E. and J.R.R.
Funding
This research was funded by ERANET-NEURON, grant DISCover (National funding institution grants: ISCIII PI09/2688 and BMBF 01EW1003, respectively, to J.R.R. and C.K.), and grants from the DFG (Ko1679/3-1), NARSAD 2013 Independent Investigator Award #20350 and EU-FP MC-ITN "IN-SENS" #607616) (C.K.); The Spanish Ministry of Science and Innovation (SAF2011-30494 and BFU2017-86692-P, partially funded by European Union regional funds (FRDER)); the Departments of Industry, Tourism and Trade (Etortek) and Innovation Technology of the Government of the Autonomous Community of the Basque Country (R.M.K. and I.G-E.); and the Spanish Ministry of Economy and Competitiveness (SAF2013-45014-R, A.G., SAF2011-30494 (R.M.K. and I.G-E.)).
Conflicts of Interest
The authors declare no conflict of interest.
Abbreviations
2-DE Two-dimensional electrophoresis
CRMP-2 Collapsing response mediator protein 2
DISC1 Disrupted in Schizophrenia 1
MAP1B Microtubule associated binding protein 1
MUNC18 Mammalian uncoordinated-18
MALDI Matrix-assisted laser desorption ionization
MS Mass Spectrometry
NCS-1 Neural calcium sensor 1
SM Sec1/Munc18-like proteins
SNARE (Soluble NSF Attachment Protein) Receptor
WB Western blot
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
1. St. Clair, D.; Blackwood, D.; Muir, W.; Walker, M.; Carothers, A.; Spowart, G.; Gosden, C.; Evans, H.J. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990, 336, 13-16.
2. Millar, J.K. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000, 9, 1415-1423. [Green Version]
3. Sachs, N.A.; Sawa, A.; Holmes, S.E.; Ross, C.A.; DeLisi, L.E.; Margolis, R.L. A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol. Psychiatry 2005, 10, 758-764. [Green Version]
4. Kim, J.Y.; Liu, C.Y.; Zhang, F.; Duan, X.; Wen, Z.; Song, J.; Feighery, E.; Lu, B.; Rujescu, D.; St Clair, D.; et al. Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 2012, 148, 1051-1064.
5. Mao, Y.; Ge, X.; Frank, C.L.; Madison, J.M.; Koehler, A.N.; Doud, M.K.; Tassa, C.; Berry, E.M.; Soda, T.; Singh, K.K.; et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009, 136, 1017-1031.
6. Lepagnol-Bestel, A.M.; Kvajo, M.; Karayiorgou, M.; Simonneau, M.; Gogos, J.A. A Disc1 mutation differentially affects neurites and spines in hippocampal and cortical neurons. Mol. Cell. Neurosci. 2013, 54, 84-92. [Green Version]
7. Zhou, M.; Li, W.; Huang, S.; Song, J.; Kim, J.Y.; Tian, X.; Kang, E.; Sano, Y.; Liu, C.; Balaji, J.; et al. MTOR Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons. Neuron 2013, 77, 647-654.
8. Hayashi-Takagi, A.; Takaki, M.; Graziane, N.; Seshadri, S.; Murdoch, H.; Dunlop, A.J.; Makino, Y.; Seshadri, A.J.; Ishizuka, K.; Srivastava, D.P.; et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat. Neurosci. 2010, 13, 327-332. [Green Version]
9. Wang, Q.; Charych, E.I.; Pulito, V.L.; Lee, J.B.; Graziane, N.M.; Crozier, R.A.; Revilla-Sanchez, R.; Kelly, M.P.; Dunlop, A.J.; Murdoch, H.; et al. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function. Mol. Psychiatry 2011, 16, 1006-1023.
10. Tsuboi, D.; Kuroda, K.; Tanaka, M.; Namba, T.; Iizuka, Y.; Taya, S.; Shinoda, T.; Hikita, T.; Muraoka, S.; Iizuka, M.; et al. Disrupted-in-schizophrenia 1 regulates transport of ITPR1 mRNA for synaptic plasticity. Nat. Neurosci. 2015, 18, 698-707.
11. Wen, Z.; Nguyen, H.N.; Guo, Z.; Lalli, M.A.; Wang, X.; Su, Y.; Kim, N.S.; Yoon, K.J.; Shin, J.; Zhang, C.; et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 2014, 515, 414-418. [Green Version]
12. Ozeki, Y.; Tomoda, T.; Kleiderlein, J.; Kamiya, A.; Bord, L.; Fujii, K.; Okawa, M.; Yamada, N.; Hatten, M.E.; Snyder, S.H.; et al. Disrupted-in-Schizophrenia-1 (DISC-1): Mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. USA 2003, 100, 289-294.
13. Namba, T.; Ming, G.-L.; Song, H.; Waga, C.; Enomoto, A.; Kaibuchi, K.; Kohsaka, S.; Uchino, S. NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via Disrupted-In-Schizophrenia 1 (DISC1). J. Neurochem. 2011, 118, 34-44. [Green Version]
14. Kamiya, A.; Kubo, K.; Tomoda, T.; Takaki, M.; Youn, R.; Ozeki, Y.; Sawamura, N.; Park, U.; Kudo, C.; Okawa, M.; et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat. Cell Biol. 2005, 7, 1167-1178.
15. Ishizuka, K.; Kamiya, A.; Oh, E.C.; Kanki, H.; Seshadri, S.; Robinson, J.F.; Murdoch, H.; Dunlop, A.J.; Kubo, K.I.; Furukori, K.; et al. DISC1-dependent switch from progenitor proliferation to migration in the developing cortex. Nature 2011, 473, 92-96. [Green Version]
16. Camargo, L.M.; Collura, V.; Rain, J.-C.; Mizuguchi, K.; Hermjakob, H.; Kerrien, S.; Bonnert, T.P.; Whiting, P.J.; Brandon, N.J. Disrupted in Schizophrenia 1 Interactome: Evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 2007, 12, 74-86.
17. Millar, J.K.; Pickard, B.S.; Mackie, S.; James, R.; Christie, S.; Buchanan, S.R.; Malloy, M.P.; Chubb, J.E.; Huston, E.; Baillie, G.S.; et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005, 310, 1187-1191.
18. Enomoto, A.; Asai, N.; Namba, T.; Wang, Y.; Kato, T.; Tanaka, M.; Tatsumi, H.; Taya, S.; Tsuboi, D.; Kuroda, K.; et al. Roles of Disrupted-In-Schizophrenia 1-Interacting Protein Girdin in Postnatal Development of the Dentate Gyrus. Neuron 2009, 63, 774-787. [Green Version]
19. Brandon, N.J.; Sawa, A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat. Rev. Neurosci. 2011, 12, 707-722. [Green Version]
20. Sialana, F.J.; Wang, A.-L.; Fazari, B.; Kristofova, M.; Smidak, R.; Trossbach, S.V.; Korth, C.; Huston, J.P.; de Souza Silva, M.A.; Lubec, G. Quantitative Proteomics of Synaptosomal Fractions in a Rat Overexpressing Human DISC1 Gene Indicates Profound Synaptic Dysregulation in the Dorsal Striatum. Front. Mol. Neurosci. 2018, 11, 26.
21. Xia, M.; Broek, J.A.C.; Jouroukhin, Y.; Schoenfelder, J.; Abazyan, S.; Jaaro-Peled, H.; Sawa, A.; Bahn, S.; Pletnikov, M. Cell Type-Specific Effects of Mutant DISC1: A Proteomics Study. Mol. Neuropsychiatry 2016, 2, 28-36. [Green Version]
22. Taya, S.; Shinoda, T.; Tsuboi, D.; Asaki, J.; Nagai, K.; Hikita, T.; Kuroda, S.; Kuroda, K.; Shimizu, M.; Hirotsune, S.; et al. DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. J. Neurosci. 2007, 27, 15-26.
23. Nagai, J.; Baba, R.; Ohshima, T. CRMPs Function in Neurons and Glial Cells: Potential Therapeutic Targets for Neurodegenerative Diseases and CNS Injury. Mol. Neurobiol. 2017, 54, 4243-4256.
24. Schmidt, E.F.; Strittmatter, S.M. The CRMP family of proteins and their role in Sema3A signaling. In Semaphorins: Receptor and Intracellular Signaling Mechanisms; Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2007.
25. Yamashita, N.; Goshima, Y. Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status. Mol. Neurobiol. 2012, 45, 234-246.
26. Nakata, K.; Ujike, H.; Sakai, A.; Takaki, M.; Imamura, T.; Tanaka, Y.; Kuroda, S. The Human Dihydropyrimidinase-Related Protein 2 Gene on Chromosome 8p21 Is Associated with Paranoid-Type Schizophrenia. Biol. Psychiatry 2003, 53, 571-576.
27. Johnston-Wilson, N.L.; Sims, C.D.; Hofmann, J.P.; Anderson, L.; Shore, A.D.; Torrey, E.F.; Yolken, R.H. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry 2000, 5, 142-149.
28. Hensley, K.; Venkova, K.; Christov, A.; Gunning, W.; Park, J. Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications. Mol. Neurobiol. 2011, 43, 180-191.
29. Wakatsuki, S.; Saitoh, F.; Araki, T. ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat. Cell Biol. 2011, 13, 1415-1423.
30. Zhang, Z.; Ottens, A.K.; Sadasivan, S.; Kobeissy, F.H.; Fang, T.; Hayes, R.L.; Wang, K.K. Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J. Neurotrauma 2007, 24, 460-472.
31. Zhang, J.-N.; Michel, U.; Lenz, C.; Friedel, C.C.; Köster, S.; d'Hedouville, Z.; Tönges, L.; Urlaub, H.; Bähr, M.; Lingor, P.; et al. Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration. Sci. Rep. 2016, 6, 37050. [Green Version]
32. Rogemond, V.; Auger, C.; Giraudon, P.; Becchi, M.; Auvergnon, N.; Belin, M.F.; Honnorat, J.; Moradi-Améli, M. Processing and nuclear localization of CRMP2 during brain development induce neurite outgrowth inhibition. J. Biol. Chem. 2008, 283, 14751-14761.
33. Alabi, A.A.; Tsien, R.W. Perspectives on Kiss-and-Run: Role in Exocytosis, Endocytosis, and Neurotransmission. Annu. Rev. Physiol. 2013, 75, 393-422.
34. Dulubova, I.; Khvotchev, M.; Liu, S.; Huryeva, I.; Su, T.C. Munc18-1 binds directly to the neuronal SNARE complex. Proc. Natl. Acad. Sci. USA 2007, 104, 2697-2702. [Green Version]
35. von Mollard, G.F.; Stahl, B.; Li, C.; Südhof, T.C.; Jahn, R. Rab proteins in regulated exocytosis. Trends Biochem. Sci. 1994, 19, 164-168.
36. Søgaard, M.; Tani, K.; Ye, R.R.; Geromanos, S.; Tempst, P.; Kirchhausen, T.; Rothman, J.E.; Söllner, T. A rab protein is required for the assembly of SNARE complexes in the docking of transport vesicles. Cell 1994, 78, 937-948.
37. Ramos, A.; Rodríguez-Seoane, C.; Rosa, I.; Trossbach, S.V.; Ortega-Alonso, A.; Tomppo, L.; Ekelund, J.; Veijola, J.; Järvelin, M.R.; Alonso, J.; et al. Neuropeptide precursor VGF is genetically associated with social anhedonia and underrepresented in the brain of major mental illness: Its downregulation by DISC1. Hum. Mol. Genet. 2014, 23, 5859-5865.
38. Niwa, M.; Cash-Padgett, T.; Kubo, K.; Saito, A.; Ishii, K.; Sumitomo, A.; Taniguchi, Y.; Ishizuka, K.; Jaaro-Peled, H.; Tomoda, T.; et al. DISC1 a key molecular lead in psychiatry and neurodevelopment: No-More Disrupted-in-Schizophrenia. Mol. Psychiatry 2016, 21, 1488-1489.
39. Bader, V.; Tomppo, L.; Trossbach, S.V.; Bradshaw, N.J.; Prikulis, I.; Rutger Leliveld, S.; Lin, C.Y.; Ishizuka, K.; Sawa, A.; Ramos, A.; et al. Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits. Hum. Mol. Genet. 2012, 21, 4406-4418. [Green Version]
40. McLean, C.K.; Narayan, S.; Lin, S.Y.; Rai, N.; Chung, Y.; Hipolito, M.M.S.; Cascella, N.G.; Nurnberger, J.I.; Ishizuka, K.; Sawa, A.S.; et al. Lithium-associated transcriptional regulation of CRMP1 in patient-derived olfactory neurons and symptom changes in bipolar disorder. Transl. Psychiatry 2018, 8, 81.
41. Pletnikov, M.V.; Ayhan, Y.; Nikolskaia, O.; Xu, Y.; Ovanesov, M.V.; Huang, H.; Mori, S.; Moran, T.H.; Ross, C.A. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry 2008, 13, 173-186.
42. Miyoshi, K.; Honda, A.; Baba, K.; Taniguchi, M.; Oono, K.; Fujita, T.; Kuroda, S.; Katayama, T.; Tohyama, M. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 2003, 8, 685-694. [Green Version]
43. Flores, R.; Hirota, Y.; Armstrong, B.; Sawa, A.; Tomoda, T. DISC1 regulates synaptic vesicle transport via a lithium-sensitive pathway. Neurosci. Res. 2011, 71, 71-77. [Green Version]
44. Ottis, P.; Bader, V.; Trossbach, S.V.; Kretzschmar, H.; Michel, M.; Leliveld, S.R.; Korth, C. Convergence of two independent mental disease genes on the protein level: Recruitment of dysbindin to cell-invasive disrupted-in-schizophrenia 1 aggresomes. Biol. Psychiatry 2011, 70, 604-610.
45. Shevchenko, A.; Wilm, M.; Vorm, O.; Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
46. Castaño, Z.; Gordon-Weeks, P.R.; Kypta, R.M. The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth. J. Neurochem. 2010, 113, 117-130.
1 CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, 15782 Santiago de Compostela, Spain
2 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD 21287, USA
3 Department of Pharmacology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
4 Cell Biology and Stem Cells Unit, CIC-bioGUNE, Parque Tecnologico de Bizkaia, 48160 Derio, Spain
5 Proteomics Unit, IDIS, 15706 Santiago de Compostela, Spain
6 Department of Neuropathology, Heinrich Heine University, Medical School, 40225 Düsseldorf, Germany
7 Department of Surgery and Cancer, Imperial College London, London W12 OUQ, UK
8 Department of Medical Sciences, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
* Correspondence: [email protected]; Tel.: +1-410-9551617
† These authors contributed equally to this work.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
[...]studies also found that the truncation of this gene in an American family segregated with cases of schizophrenia [3]. Since the discovery of this translocation, many groups have invested their efforts in understanding the role of DISC1 protein, with the hope of revealing new mechanisms that could explain the neurobiology behind mental disease. [...]DISC1 was proposed to be involved in diverse processes such as neurogenesis [4,5], synapse regulation [6,7,8,9,10], neurite outgrowth [6,11,12], and neural migration and proliferation [13,14,15]. The absence of DISC1 in this cell line resulted in morphological changes (Figure 2). [...]upon retinoic acid-induced differentiation, DISC1-silenced cells exhibited fewer and shorter neurites (Figure 2, Figure S4). Previous studies have reported an impaired neurite outgrowth in cell models that overexpress mutant isoforms of DISC1 [11,41] and an increase of neurite outgrowth was seen in PC12 cells that overexpress DISC1 [42]. [...]our study reinforces the idea that the loss of function of DISC1 is critical for proper regulation of neurite outgrowth.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer